Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

NCT05736978 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

AML
MRD

Interventions

DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Selinexor

Sponsor

Shanghai Tong Ren Hospital